Biogen

FDA Adviser Quits Over 'Probably The Worst' Approval Decision Of Alzheimer's Drug

The controversial drug, called Aduhelm, costs $56,000 a year and some patients could face copayments of $11,500 annually.
By RICARDO ALONSO-ZALDIVAR and MATTHEW PERRONE, AP

FDA Approves Much-Debated Alzheimer’s Drug Panned By Experts

Independent advisers had warned that the much-debated treatment developed by Biogen hasn’t been shown to help slow the brain-destroying disease.
By MATTHEW PERRONE, AP

This Company Turns Food Waste Into Energy

Biogen uses anaerobic digestion to convert unwanted food into biofertilizer for crops and renewable electricity.
ByÂ